Efficacy of Transcutaneous Electrical Neural Stimulation and Tadalafil in Men With Erectile Dysfunction: A Randomized, Double-Blind, Bi-centric, Placebo- and Sham-Controlled Trial
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Menoufia University
- Enrollment
- 185
- Locations
- 1
Study Overview
Brief Summary
Organic erectile failure is thought to be caused predominantly by neurogenic or vascular disorders. Venoocclusive dysfunction of the corpora cavernosa induces erectile dysfunction in 20-30% and appears clinically by premature erection loss.
The increased venous outflow from the corpora cavernosa can be illustrated as a so called 'venous leakage' by cavernosography being responsible for the therapeutical failure of intracavernously applied vasoactive substances. Cavernous smooth muscle pathology proven in some of the patients with venous leakage gave little hope to reconstructive surgery.
However, own examinations let assume that the etiology of 'venous leakage' is caused by endogenic and exogenic factors. Furthermore, reversible venous leakage was observed. Any therapeutic option of the veno-occlusive dysfunction showed disappointing results with a respective success rate of 20% in the long-term follow-up (surgical venous resection, percutaneous transpenile venous embolisms).
Finally the vacuum device or penile prosthetics are the only therapeutical option for the patients. Physiologically, bulbocavernous and ischiocavernous muscles increase the intracavernous pressure of the tumescent penis.
Regular pelvic floor exercise can be achieved by a physiotherapist which seems to be a time-consuming and expensive procedure, or an advantageous transcutaneous electrical stimulation which is the standard therapy for the treatment of posttraumatic atrophy of the striated muscular system.
Thus an external stimulator device has been developed to evaluate the therapeutical potency of striated muscle exercise in patients with erectile dysfunction. The present clinical study documents the first experiences with this EIS device and outlines its potency for the treatment of erectile dysfunction.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •clinical diagnosis of erectile dysfunction for at least 6 months and confirmed with penile color doppler ultrasound
Exclusion Criteria
- •Patients with history of cardiovascular disease, contraindication for phosphodiesterase type 5 inhibitor, implanted cardiac pacemakers or defibrillators, anatomically significant penile deformities, active skin lesions at the electrode placement sites or any untreated endocrinal disorder that could affect the erectile function
Arms & Interventions
Sham-placebo
This group will receive Sham stimulation along with Placebo similar to tadalafil
Intervention: Sham stimulation (Device)
Active-Placebo
This group will receive active stimulation along with Placebo similar to tadalafil
Intervention: Active TENS (Device)
Sham-Tadalafil
This group will receive Sham stimulation along with tadalafil
Intervention: Tadalafil 5 mg (Drug)
Sham-Tadalafil
This group will receive Sham stimulation along with tadalafil
Intervention: Sham stimulation (Device)
Active-Tadalafil
This group will receive active stimulation along with tadalafil
Intervention: Active TENS (Device)
Sham-placebo
This group will receive Sham stimulation along with Placebo similar to tadalafil
Intervention: Placabo (Drug)
Active-Placebo
This group will receive active stimulation along with Placebo similar to tadalafil
Intervention: Placabo (Drug)
Active-Tadalafil
This group will receive active stimulation along with tadalafil
Intervention: Tadalafil 5 mg (Drug)
Investigators
Ammar Fathi Mohamed AlOrabi
Doctor
Menoufia University
